Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.40 |
| ▸ | SELL | P14151 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
| ▸ | SELE | P16581 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365000 | 1.00 | ERN1 (0.54) | ERN1MAPTALDH1A1MEN1USP2 | |
| SCHEMBL14922836 | 0.89 | MAPT (0.43) | ERN1MAPTALDH1A1MEN1USP2 | |
| SCHEMBL8942952 | 0.89 | MAPT (0.43) | ERN1MAPTALDH1A1MEN1USP2 | |
| SCHEMBL8942958 | 0.89 | MAPT (0.43) | ERN1MAPTALDH1A1MEN1USP2 | |
| SCHEMBL11338030 | 0.82 | SMN1; SMN2 (0.59) | ERN1MAPTALDH1A1MEN1USP2 | |
| SCHEMBL6824495 | 0.82 | ERN1 (0.64) | ERN1MAPTALDH1A1MEN1USP2 | |
| SCHEMBL6824492 | 0.82 | ERN1 (0.64) | ERN1MAPTALDH1A1MEN1USP2 | |
| SCHEMBL20806240 | 0.80 | MAPT (0.39) | MAPTALDH1A1MEN1USP2GAA | |
| SCHEMBL9174210 | 0.76 | MAPT (0.55) | MAPTALDH1A1MEN1USP2GAA | |
| SCHEMBL6819211 | 0.76 | MAPT (0.65) | MAPTALDH1A1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | ERN1 2392/4885MAPT 15/4885ALDH1A1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.